FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy(Fred Hutchinson Cancer Center)

N/A

Report date: 2025/06/28 20:00:07

Base Information

Drug NameFH-FOLR1 Chimeric Antigen Receptor T Cell Therapy(Fred Hutchinson Cancer Center)
Drug Alias NameFOLR1 CAR T Cell Therapy(Fred Hutchinson Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsFolate receptor alpha modulators
TargetsFolate receptor alpha
Therapy Area/IndicationsOsteosarcomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsOsteosarcomaLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A